News
ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer Yahoo/BusinessWire
View ArticleT-DM1 Significantly Improved Progression-Free Survival Compared to Standard...
T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer Yahoo/GlobeNewswire
View ArticleSynthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for...
Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for Trastuzumab Pipeline Review
View ArticleThis Cancer Drug Works, but Indication Drama Remains
This Cancer Drug Works, but Indication Drama Remains Motley Fool
View ArticleImmunoGen, Surprisingly Quiet Ahead Of FDA Decision
ImmunoGen, Surprisingly Quiet Ahead Of FDA Decision Seeking Alpha
View ArticleAfter FDA Approval, A New And Bigger Catalyst Looms Closer For Immunogen
After FDA Approval, A New And Bigger Catalyst Looms Closer For Immunogen Seeking Alpha
View ArticleBiosimilars Could Be An Unlikely Boost For Pfizer
Biosimilars Could Be An Unlikely Boost For Pfizer Seeking Alpha
View ArticleBiocon to start selling breast cancer drug in India in February
Biocon to start selling breast cancer drug in India in February Yahoo/Reuters
View Article
